[go: up one dir, main page]

PE20091313A1 - (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina - Google Patents

(r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina

Info

Publication number
PE20091313A1
PE20091313A1 PE2009000004A PE2009000004A PE20091313A1 PE 20091313 A1 PE20091313 A1 PE 20091313A1 PE 2009000004 A PE2009000004 A PE 2009000004A PE 2009000004 A PE2009000004 A PE 2009000004A PE 20091313 A1 PE20091313 A1 PE 20091313A1
Authority
PE
Peru
Prior art keywords
pirazin
tetrahydropyran
phenyl
crystalline
cyclopropansulfonil
Prior art date
Application number
PE2009000004A
Other languages
English (en)
Inventor
Jeanette Tower Dunlap
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091313(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20091313A1 publication Critical patent/PE20091313A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO CRISTALINO DE R-2-(4-CICLOPROANSULFONIL-FENIL)-N-PIRAZIN-2-IL-3-(TETRAHIDROPIRAN-4-IL)-PROPANAMIDA CARACTERIZADA POR UN PATRON DE DIFRACCION EN POLVO DE RAYOS X SE OBTIENE DE UNA FUENTE CuKALFA(LAMBDA=1.54056AMSTRONG), EL CUAL COMPRENDE PICOS A: 11.5 Y 19.0 +/- 0.1 EN 2 THETA. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE ADEMAS UN AGENTE DIABETICO O AGENTE ANTIHIPERGLICEMICO. DICHO COMPUESTO ES ACTIVADOR DE GLUCOCINASA UTIL EN LA PREVENCION Y TRATAMIENTO DE HIPERGLICEMIA
PE2009000004A 2008-01-15 2009-01-05 (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina PE20091313A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2113308P 2008-01-15 2008-01-15

Publications (1)

Publication Number Publication Date
PE20091313A1 true PE20091313A1 (es) 2009-09-03

Family

ID=40451065

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000004A PE20091313A1 (es) 2008-01-15 2009-01-05 (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina

Country Status (22)

Country Link
US (1) US20090181981A1 (es)
EP (1) EP2265271A1 (es)
JP (1) JP2011509934A (es)
KR (1) KR20100092061A (es)
CN (1) CN101909629A (es)
AR (1) AR070107A1 (es)
AU (1) AU2009205606A1 (es)
BR (1) BRPI0907165A2 (es)
CA (1) CA2712245A1 (es)
CL (1) CL2009000004A1 (es)
CO (1) CO6280489A2 (es)
DO (1) DOP2010000216A (es)
EA (1) EA201070853A1 (es)
EC (1) ECSP10010347A (es)
IL (1) IL206102A0 (es)
MA (1) MA31985B1 (es)
MX (1) MX2010007784A (es)
PE (1) PE20091313A1 (es)
TN (1) TN2010000299A1 (es)
TW (1) TW200934772A (es)
WO (1) WO2009091634A1 (es)
ZA (1) ZA201003909B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA08290520B1 (ar) 2007-08-22 2012-02-22 استرازينيكا ايه بي مشتقات سيكلو بروبيل أميد وتركيبات صيدلية تحتوي عليها لعلاج حالة مرضية سببها مستقبلات هيستامين h3
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
SG10201501226VA (en) * 2010-02-18 2015-04-29 Astrazeneca Ab New crystalline form of a cyclopropyl benzamide derivative
MX2012009537A (es) * 2010-02-18 2012-08-31 Astrazeneca Ab Formas solidas que comprenden un derivado de ciclopropilamida.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101220371B1 (ko) 2010-09-17 2013-01-09 현대자동차주식회사 베인펌프
EP2674517B1 (en) * 2011-02-08 2018-10-03 Japan Agency for Marine-Earth Science and Technology Method for producing calcite single crystal
JP2013014534A (ja) * 2011-07-04 2013-01-24 Daicel Corp ベンゾイルギ酸化合物、及びその製造方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046768A (en) * 1976-06-17 1977-09-06 Velsicol Chemical Corporation 1-Thiazolyl-5-pyridylcarbonyloxyimidazolidinones
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
US6353111B1 (en) * 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
US6388071B2 (en) * 2000-05-03 2002-05-14 Hoffmann-La Roche Inc. Alkynyl phenyl heteroaromatic glucokinase activators
US6489485B2 (en) * 2000-05-08 2002-12-03 Hoffmann-La Roche Inc. Para-amine substituted phenylamide glucokinase activators
MXPA02010796A (es) * 2000-05-08 2003-03-27 Hoffmann La Roche Fenilacetamidas sustituidas y sus usos como activadores de glucocinasa.
KR100556323B1 (ko) * 2000-07-20 2006-03-03 에프. 호프만-라 로슈 아게 알파-아실 및 알파-헤테로원자-치환된 벤젠 아세트아미드글루코키나제 활성화제
US6369232B1 (en) * 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
US6433188B1 (en) * 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
DE60117059T2 (de) * 2000-12-06 2006-10-26 F. Hoffmann-La Roche Ag Kondensierte heteroaromatische glucokinaseaktivatoren
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
US6911545B2 (en) * 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
WO2004072066A1 (en) * 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
MXPA06012008A (es) * 2004-04-21 2007-01-25 Prosidion Ltd Compuestos de amida tri(ciclo) sustituidos.
KR20080105180A (ko) * 2004-08-12 2008-12-03 프로시디온 리미티드 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의 그의 용도
GB0418046D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
GB0418058D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
US20080293741A1 (en) * 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
JP2009514836A (ja) * 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
BRPI0618062A2 (pt) * 2005-11-03 2011-08-16 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto

Also Published As

Publication number Publication date
WO2009091634A1 (en) 2009-07-23
JP2011509934A (ja) 2011-03-31
US20090181981A1 (en) 2009-07-16
IL206102A0 (en) 2010-11-30
EP2265271A1 (en) 2010-12-29
CA2712245A1 (en) 2009-07-23
EA201070853A1 (ru) 2010-12-30
TW200934772A (en) 2009-08-16
ZA201003909B (en) 2011-11-30
CL2009000004A1 (es) 2010-02-19
MA31985B1 (fr) 2011-01-03
DOP2010000216A (es) 2010-10-15
AR070107A1 (es) 2010-03-17
BRPI0907165A2 (pt) 2015-07-14
TN2010000299A1 (en) 2011-11-11
KR20100092061A (ko) 2010-08-19
CO6280489A2 (es) 2011-05-20
AU2009205606A1 (en) 2009-07-23
MX2010007784A (es) 2010-08-09
ECSP10010347A (es) 2010-09-30
CN101909629A (zh) 2010-12-08

Similar Documents

Publication Publication Date Title
PE20091313A1 (es) (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
WO2006119283A3 (en) Anti-odor compositions and therapeutic use
PE20100265A1 (es) Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
DK1845095T3 (da) 1-thio-D-glucitolderivater
NZ628096A (en) Cycloalkyloxy-n-substituted-benzenesulfonamide derivatives and uses thereof for treatment or prevention of pain
CR11441A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
EP2070509A3 (en) The use of Myrica gale oil
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
ECSP10010160A (es) Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep)
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
EP2349279A4 (en) MODIFIERS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF
CL2008000133A1 (es) Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
ATE454372T1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
TNSN07419A1 (en) Methods for treating drug resistant cancer
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
PE20110019A1 (es) Composicion farmaceutica que contiene un sensibilizante de insulina y un secretagogo de insulina
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica
UA109627C2 (uk) Композиції тетрациклінових сполук для орального введення та ін'єкцій
FR2967578B1 (fr) Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie
EP1584335A3 (en) Active substance combination comprising a carbinol composition and an opioid
RU2012145176A (ru) Композиции против эндопаразитов

Legal Events

Date Code Title Description
FD Application declared void or lapsed